Related Experiment Videos
Hepatoma/merbarone. A Southwest Oncology Group study
E A Poplin1, C M Tangen, W H Harvey
1Wayne State University Medical Center, Detroit, MI, USA.
Investigational New Drugs
|January 1, 1994
Abstract:
Sixteen eligible patients with hepatocellular carcinoma, previously untreated, received merbarone 1000 mg/m2/d for five consecutive days every 21 days. No complete or partial response to treatment was obtained. Seven patients had grade 4 granulocytopenia. One patient died with renal failure. Merbarone in this dose and schedule was ineffective in the treatment of hepatocellular carcinoma.